BRIEF: Cloudbreak tumbles in Hong Kong trading debut
2592.HK
Ophthalmic biotech company Cloudbreak Pharma Inc. (2592.HK) opened down 6% in its Hong Kong trading debut on Wednesday, and continued to fall during the morning session to close down 30% at HK$7.04 by the midday break.
The company sold 60.58 million shares for HK$10.10 apiece to raise net proceeds of about HK$ 522 million ($66 million). The public offering for local Hong Kong investors was oversubscribed by 78 times, while the international placement was undersubscribed.
Cloudbreak recorded no revenue in 2022 or 2023, and booked just $10 million in 2024. Its net loss last year stood at $99.13 million, narrower by 23% year-on-year.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, clickhere
Related Articles
RELATED ARTICLES
-
BRIEF: Cloudbreak launches $78 million Hong Kong IPO
2592.HK -
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
BRIEF: MetaLight tumbles in Hong Kong trading debut
2605.HK
-
BRIEF: CaoCao tumbles in Hong Kong trading debut
2643.HK
-
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
9606.HK
